Summary of FDA workshop on ischemia reperfusion injury in kidney transplantation

American Journal of Transplantation

Volumn 13, Issue 5, 2013, Pages 1134-1148

  Cavaille Coll M ^a   Bala, S ^a   Velidedeoglu, E ^a   Hernandez, A ^b   Archdeacon, P ^c   Gonzalez, G ^b   Neuland, C ^b   Meyer, J ^a   Albrecht, R ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^b Center for Devices and Radiologic Health   (United States)

^c CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

Clinical trials; delayed graft function; efficacy; endpoints; ischemia reperfusion injury; safety

Indexed keywords

ACTIVATED PROTEIN C; CYCLOSPORIN A; DOPAMINE; ENLIMOMAB; FENOLDOPAM; FUROSEMIDE; HIGH MOBILITY GROUP B1 PROTEIN; INTERLEUKIN 17; OMNIBONIA; PENTOXIFYLLINE; RECOMBINANT ERYTHROPOIETIN; THYMOCYTE ANTIBODY; TOLL LIKE RECEPTOR 4; TRANSCRIPTOME; UNCLASSIFIED DRUG; VITAMIN; VON WILLEBRAND FACTOR;

ADAPTIVE IMMUNITY; BRAIN DEATH; COLD ISCHEMIA; CONFERENCE PAPER; CRYOPRESERVATION; DELAYED GRAFT FUNCTION; DONOR SELECTION; ENDOTHELIAL DYSFUNCTION; FOOD AND DRUG ADMINISTRATION; GRAFT RECIPIENT; GRAFT SURVIVAL; HISTOPATHOLOGY; HUMAN; INNATE IMMUNITY; ISCHEMIA; KIDNEY BIOPSY; KIDNEY DONOR; KIDNEY TRANSPLANTATION; NONHUMAN; ORGAN PRESERVATION; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PERIPHERAL ISCHEMIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REPERFUSION INJURY;

ANIMALS; CONGRESSES AS TOPIC; DELAYED GRAFT FUNCTION; KIDNEY TRANSPLANTATION; ORGAN PRESERVATION; REPERFUSION INJURY; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84876908152     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/ajt.12210     Document Type: Conference Paper

References (63)

1. Effects of Ischemia Reperfusion Injury on Outcomes in Kidney Transplantation; FDA Public Workshop: http://www.fda.gov/Drugs/NewsEvents/ ucm263860.htm.
2. Yarlagadda SG, Coca SG, Garg AX, Doshi M, Poggio E, Marcus RJ, et al. Marked variation in the definition and diagnosis of delayed graft function: A systematic review. Nephrol Dial Transplant 2008; 23: 2995-3003.
3. Burne-Taney MJ, Kofler J, Yokota N, Weisfeldt M, Traystman RJ, Rabb H., Acute renal failure after whole body ischemia is characterized by inflammation and T cell-mediated injury. Am J Physiol Renal Physiol 2003; 285: F87-F94.
4. Li X, Liu M, Bedja D, Thoburn C, Gabrielson K, Racusen LC, et al. Acute renal venous obstruction is more detrimental to the kidney than arterial occlusion-implication for murine models of acute kidney injury. Am J Physiol Renal Physiol 2012; 302: F519-F525.
5. Yang L, Besschetnova TY, Brooks CR, Shah JV, Bonventre JV., Epithelial cell cycle arrest in G2/M mediates kidney fibrosis after injury. Nat Med 2010; 16: 535-543.
6. Chen G, Bridenbaugh EA, Akintola AD, Catania JM, Vaidya VS, Bonventre JV, et al. Increased susceptibility of aging kidney to ischemic injury: Identification of candidate genes changed during aging, but corrected by caloric restriction. Am J Physiol Renal Physiol 2007; 293: F1272-F1281.
7. Nozaki T, Amano H, Bickerstaff A, Orosz CG, Novick AC, Tanabe K, et al. Antibody-mediated rejection of cardiac allografts in CCR5-deficient recipients. J Immunol 2007; 179: 5238-5245.
8. Kolber-Simonds D, Lai L, Watt SR, Denaro M, Arn S, Augenstein ML, et al. Production of α-1,3-galactosyltransferase null pigs by means of nuclear transfer with fibroblasts bearing loss of heterozygosity. Proc Natl Acad Sci USA 2004; 101: 7335-7340.
9. Purins K, Purins K, Sedigh A, Molnar C, Jansson L, Korsgren O, et al. Standardized experimental brain death model for studies of intracranial dynamics, organ preservation, and organ transplantation in the pig. Crit Care Med 2011; 39: 512-517.
10. Hanto DW, Maki T, Yoon MH, Csizmadia E, Chin BY, Gallo D, et al. Intraoperative administration of inhaled carbon monoxide reduces delayed graft function in kidney allografts in swine. Am J Transplant 2010; 10: 2421-2430.
11. Saotome T, Ishikawa K, May CN, Birchall IE, Bellomo R., The impact of experimental hypoperfusion on subsequent kidney function. Intensive Care Med 2010; 36: 533-540.
12. Novitzky D, Horak A, Cooper DK, Rose AG., Electrocardiographic and histopathologic changes developing during experimental brain death in the baboon. Transplant Proc; 1989; 21: 2567-2569.
13. Lu CY, Winterberg PD, Chen J, Hartono JR., Acute kidney injury: A conspiracy of toll-like receptor 4 on endothelia, leukocytes, and tubules. Pediatr Nephrol 2012; 27: 1847-1854.
14. Chen J, John R, Richardson JA, Shelton JM, Zhou XJ, Wang Y, et al. Toll-like receptor 4 regulates early endothelial activation during ischemic acute kidney injury. Kidney Int 2011; 79: 288-299.
15. Kinsey GR, Li L, Okusa MD., Inflammation in acute kidney injury. Nephron Exp Nephrol 2008; 109: e102-e107.
16. Sis B, Mengel M, Haas M, Colvin RB, Halloran PF, Racusen LC, et al. Banff '09 meeting report: Antibody mediated graft deterioration and implementation of Banff working groups. Am J Transplant 2010; 10: 464-471.
17. Kwon O, Hong SM, Sutton TA, Temm CJ., Preservation of peritubular capillary endothelial integrity and increasing pericytes may be critical to recovery from postischemic acute kidney injury. Am J Physiol Renal Physiol 2008; 295: F351-F359.
18. Gwinner W, Hinzmann K, Erdbruegger U, Scheffner I, Broecker V, Vaske B, et al. Acute tubular injury in protocol biopsies of renal grafts: Prevalence, associated factors and effect on long-term function. Am J Transplant 2008; 8: 1684-1693.
19. Parikh CR, Jani A, Mishra J, Ma Q, Kelly C, Barasch J, et al. Urine NGAL and IL-18 are predictive biomarkers for delayed graft function following kidney transplantation. Am J Transplant 2006; 6: 1639-1645.
20. Mengel M, Chang J, Kayser D, Gwinner W, Schwarz A, Einecke G, et al. The molecular phenotype of 6 week protocol biopsies from human renal allografts: Reflections of prior injury not future course. Am J Transplant 2011; 11: 708-718.
21. Mueller TF, Reeve J, Jhangri GS, Mengel M, Jacai Z, Cairo L, et al. The transcriptome of the implant biopsy identifies donor kidneys at increased risk of delayed graft function. Am J Transplant 2008; 8: 78-85.
22. Halloran PF, de Freitas DG, Einecke G, Famulski KS, Hidalgo LG, Mengel M, et al. The molecular phenotype of kidney transplants. Am J Transplant 2010; 10: 2215-2222.
23. Cockfield SM, Moore RB, Todd G, Solez K, Gourishankar S., The prognostic utility of deceased donor implantation biopsy in determining function and graft survival after kidney transplantation. Transplantation 2010; 89: 559-566.
24. Matignon M, Desvaux D, Noel LH, Roudot-Thoraval F, Thervet E, Audard V, et al. Arteriolar hyalinization predicts delayed graft function in deceased donor renal transplantation. Transplantation 2008; 86: 1002-1005.
25. Cohen DJ, St. Martin L, Christensen LL, Bloom RD, Sung RS., Kidney and pancreas transplantation in the United States, 1995-2004. Am J Transplant 2006; 6: 1153-1169.
26. Locke JE, Segev DL, Warren DS, Dominici F, Simpkins CE, Montgomery RA., Outcomes of kidneys from donors after cardiac death: Implications for allocation and preservation. Am J Transplant 2007; 7: 1797-1807.
27. Terasaki PI, Cecka JM, Gjertson DW, Cho YW., Spousal and other living renal donor transplants. Clin Transpl 1997; 269-284.
28. Kayler LK, Garzon P, Magliocca J, Fujita S, Kim RD, Hemming AW, et al. Outcomes and utilization of kidneys from deceased donors with acute kidney injury. Am J Transplant 2009; 9: 367-373.
29. Doshi MD, Garg N, Reese PP, Parikh CR., Recipient risk factors associated with delayed graft function: A paired kidney analysis. Transplantation 2011; 91: 666-671.
30. Kayler LK, Magliocca J, Zendejas I, Srinivas TR, Schold JD., Impact of cold ischemia time on graft survival among ECD transplant recipients: A paired kidney analysis. Am J Transplant 2011; 12: 2647-2656.
31. Land WG., The role of postischemic reperfusion injury and other nonantigen-dependent inflammatory pathways in transplantation. Transplantation 2005; 79: 505-514.
32. Halloran PF, Homik J, Goes N, Lui SL, Urmson J, Ramassar V, et al. The "injury response": A concept linking nonspecific injury, acute rejection, and long-term transplant outcomes. Transplant Proc 1997; 29: 79-81.
33. Troppmann C, Gillingham K, Gruessner R, Dunn D, Payne W, Najarian J, et al. Delayed graft function in the absence of rejection has no long-term impact: A study of cadaver kidney recipients with good graft function at 1 year after transplantation. Transplantation 1996; 61: 1331-1337.
34. Humar A, Ramcharan T, Kandaswamy R, Gillingham K, Payne WD, Matas AJ., Risk factors for slow graft function after kidney transplants: A multivariate analysis. Clin Transplant 2002; 16: 425-429.
35. Guidance for the Content of Investigational Device Exemptions for Solutions for Hypothermic Flushing, Transport and Storage of Organs for Transplantation; Guidance for Industry and FDA Reviewers; January 16, 2011: http://www.fda.gov/downloads/MedicalDevices/DeviceRegulationandGuidance/ GuidanceDocuments/ucm073654.pdf.
36. Draft Guidance for Industry and Food and Drug Administration Staff, the 510(k) Program: Evaluating Substantial Equivalence in Premarket Notifications [510(k)], http://www.fda.gov/downloads/MedicalDevices/ DeviceRegulationandGuidance/GuidanceDocuments/UCM284443.pdf.
37. OPTN/SRTR Annual Report, Chapter II. Organ Donation and Utilization in the United States, 1999-2008: http://www.ustransplant.org/annual-reports/ current/Chapter-II-AR-CD.htm?cp=3#2.
38. Guidance for Industry, E9 Statistical Principles for Clinical Trials, September 1998: http://www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatoryInformation/Guidances/UCM073137.pdf.
39. Guidance for Industry, Adaptive Design Clinical Trials for Drugs and Biologics, Draft Guidance, February 2010: http://www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatoryInformation/Guidances/UCM201790.pdf.
40. Irish WD, Ilsley JN, Schnitzler MA, Feng S, Brennan DC., A risk prediction model for delayed graft function in the current era of deceased donor renal transplantation. Am J Transplant 2010; 10: 2279-2286.
41. Guidance for Industry, Exposure-Response Relationships-Study Design, Data Analysis, and Regulatory Applications. April 2003: http://www.fda.gov/ downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM072109.pdf.
42. Pepe MS, Etzioni R, Feng Z, Potter JD, Thompson ML, Thornquist M, et al. Phases of biomarker development for early detection of cancer. J Natl Cancer Inst 2001; 93: 1054-1061.
43. Lachance SL, Barry JM., Effect of furosemide on dialysis requirement following cadaveric kidney transplantation. J Urol 1985; 133: 950-951.
44. Michael HJ, Francos GC, Burke JF, Besarab A, Moritz M, Gillum D, et al. A comparison of the effects of cyclosporine versus antilymphocyte globulin on delayed graft function in cadaver renal transplant recipients. Transplantation 1989; 48: 805-808.
45. Rabl H, Khoschsorus G, Colombo T, Petritsch P, Rauchenwald M, Koltringer P, et al. A multivitamin infusion prevents lipid peroxidation and improves transplantation performance. Kidney Int 1993; 43: 912-917.
46. Hazzan NC, Coppin MC, Codaccioni MX, Pruvot FR, Lelievre G., A randomized controlled trial of pentoxifylline for the prevention of delayed graft function in cadaveric kidney graft. Clin Transplant 1997; 11: 169-173.
47. Salmela K, Wramner L, Ekberg H, Hauser I, Bentdal O, Lins LE, et al. A randomized multicenter trial of the anti-ICAM-1 monoclonal antibody (enlimomab) for the prevention of acute rejection and delayed onset of graft function in cadaveric renal transplantation: A report of the European anti-ICAM-1 renal transplant study group. Transplantation 1999; 67: 729-736.
48. Goggins WC, Pascual MA, Powelson JA, Magee C, Tolkoff-Rubin N, Farrell ML, et al. A prospective, randomized, clinical trial of intraoperative versus postoperative thymoglobulin in adult cadaveric renal transplant recipients. Transplantation 2003; 76: 798-802.
49. Hladunewich MA, Corrigan G, Derby GC, Ramaswamy D, Kambham N, Scandling JD, et al. A randomized, placebo-controlled trial of IGF-1 for delayed graft function: A human model to study postischemic ARF. Kidney Int 2003; 64: 593-602.
50. Fontana I, Germi MR, Beatini M, Fontana S, Bertocchi M, Porcile E, et al. Dopamine "renal dose" versus fenoldopam mesylate to prevent ischemia-reperfusion injury in renal transplantation. Transplant Proc 2005; 37: 2474-2475.
51. Shilliday IR, Sherif M., Calcium channel blockers for preventing acute tubular necrosis in kidney transplant recipients. Cochrane Database Syst Rev 2007; 17: CD003421.
52. Martinez F, Kamar N, Pallet N, Lang P, Durrbach A, Lebranchu Y, et al. High dose epoetin beta in the first weeks following renal transplantation and delayed graft function: Results of the Neo-PDGF study. Am J Transplant 2010; 10: 1695-1700.
53. Roels L, Coosemans W, Donck J, Maes B, Peeters J, Vanwalleghem J, et al. Inferior outcome of cadaveric kidneys preserved for more than 24 hr in histidine-tryptophan-ketoglutarate solution. Transplantation 1998; 66: 1660-1664.
54. de Boer J, De Meester J, Smits JM, Groenewoud AF, Bok A, van der Velde O, et al. Eurotransplant randomized multicenter kidney graft preservation study comparing HTK with UW and Euro-Collins. Transpl Int 1999; 12: 447-453.
55. Agarwal A, Murdock P, Fridell JA., Comparison of histidine-tryptophan- ketoglutarate solution and University of Wisconsin solution in prolonged cold preservation of kidney allografts. Transplantation 2006; 81: 480-482.
56. Klaus F, Castro DB, Bittar CM, Bittar AE, Keitel E, Seelig DC, et al. Kidney transplantation with Belzer or Custodiol solution: A randomized prospective study. Transplant Proc 2007; 39: 353-354.
57. Lynch RJ, Kubus J, Chenault RH, Pelletier SJ, Campbell DA, Englesbe MJ., Comparison of histidine-tryptophan-ketoglutarate and University of Wisconsin preservation in renal transplantation. Am J Transplant 2008; 8: 567-573.
58. Stevens RB, Skorupa JY, Rigley TH, Yannam GR, Nielsen KJ, Schriner ME, et al. Increased primary non-function in transplanted deceased-donor kidneys flushed with histidine-tryptophan-ketoglutarate solution. Am J Transplant 2009; 9: 1055-1062.
59. Opelz G, Döhler B., Multicenter analysis of kidney preservation. Transplantation 2007; 83: 247-253.
60. Stewart ZA, Lonze BE, Warren DS, Dagher NN, Singer AL, Montgomery RA, et al. Histidine-tryptophan-ketoglutarate (HTK) is associated with reduced graft survival of deceased donor kidney transplants. Am J Transplant 2009; 9: 1048-1054.
61. Wight JP, Chilcott JB, Holmes MW, Brewer N., Pulsatile machine perfusion vs. cold storage of kidneys for transplantation: A rapid and systematic review. Clin Transplant 2003; 17: 293-307.
62. Moers C, Smits JM, Maathuis MH, Treckmann J, van Gelder F, Napieralski BP, et al. Machine perfusion or cold storage in deceased-donor kidney transplantation. N Engl J Med 2009; 360: 7-19.
63. Watson CJ, Wells AC, Roberts RJ, Akoh JA, Friend PJ, Akyol M, et al. Cold machine perfusion versus static cold storage of kidneys donated after cardiac death: A UK multicenter randomized controlled trial. Am J Transplant 2010; 10: 1991-1999.